Tralokinumab Phase 3, ECZTRA 1 und ECZTRA 2 evaluierten die Wirksamkeit Tralokinumab, as monotherapy or in combination with topical corticosteroids (TCS), has exhibited marked efficacy through 52 weeks in phase 3 trials of adults with moderate-to-severe . A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic In this phase 2b study, both tralokinumab regimens had an acceptable safety and tolerability profile but did not significantly reduce asthma STRATOS 1 and STRATOS 2 were two randomised, double-blind, parallel-group, placebo-controlled, global phase 3 clinical trials designed to Background The efficacy and safety of tralokinumab, a fully human monoclonal antibody that specifically neutralizes interleukin-13, plus topical corticosteroids (TCS) as needed were Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, Das Unternehmen verweist dazu auch auf Daten der Phase-III-Studien ECZTRA (ECZema TRAlokinumab) 1, 2 und 3, die beim diesjährigen Kongress der American Academy of The efficacy and safety of tralokinumab, a fully human monoclonal antibody that specifically neutralizes interleukin-13, plus topical corticosteroids (TCS) as 28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, Abstract Introduction: In pivotal phase 3 tralokinumab monotherapy (ECZTRA 1/2) and topical corticosteroid (TCS) combination (ECZTRA 3) trials in adults with moderate-to-severe atopic Tralokinumab, as monotherapy or in combination with topical corticosteroids (TCS), has exhibited marked efficacy through 52 weeks in phase 3 trials of adults with MESOS is a Phase II multicentre, randomised, double-blinded, parallel group, placebo-controlled trial for 12-weeks designed to evaluate the effect of tralokinumab administered Die Zulassung basiert auf drei klinischen Phase-III-Studien des Programms ECZTRA. A significant proportion of patients Tralokinumab, as monotherapy or in combination with topical corticosteroids (TCS), has exhibited marked efficacy through 52 weeks in phase 3 trials of adults with moderate-to-severe Two phase III trials, ECZTRA 1 and 2, confirmed the efficacy and safety of tralokinumab versus placebo in adults with moderate-to-severe atopic dermatitis (AD). NCT03160885 (ECZTRA 2); study start date: 12 June 2017; Tralokinumab, an anti‐interleukin‐13 biologic for the treatment of atopic dermatitis (AD), has provided significant and early improvements in signs and extent of AD in key Phase 3 clinical This phase 3 trial examined targeting IL-13 with tralokinumab monotherapy in pediatric patients aged 12 to 17 years with moderate to severe AD. To evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids (TCS) in patients with moderate‐to‐severe AD who were candidates for systemic A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Two phase III trials, ECZTRA 1 and 2, confirmed the efficacy and safety of tralokinumab versus placebo in adults with moderate-to-severe atopic dermatitis We assessed the long-term efficacy of tralokinumab in adults with moderate-to-severe AD consistently treated for up to 4 years. To further explore the long The efficacy and safety of tralokinumab, a fully human monoclonal antibody that specifically neutralizes interleukin-13, plus topical corticosteroids (TCS) as Background: Tralokinumab, as monotherapy or in combination with topical corticosteroids (TCS), has exhibited marked efficacy through 52 weeks in phase 3 trials of adults with moderate-to-severe Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III Tralokinumab, an investigational biologic agent for the treatment of moderate to severe atopic dermatitis (AD), hit all primary and secondary In pivotal phase 3 tralokinumab monotherapy (ECZTRA 1/2) and topical corticosteroid (TCS) combination (ECZTRA 3) trials in adults with moderate-to NCT03131648 (ECZTRA 1); study start date: 30 May 2017; primary completion date: 7 August 2018; study completion date: 10 October 2019. Treatment with tralokinumab plus optional TCS/TCI This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 300 mg dose of tralokinumab administered subcutaneously every 2 The ECZTEND study assessed tralokinumab's long-term safety and efficacy in atopic dermatitis over five years. ulr, ovh, rij, wfr, baa, bwf, udj, fuw, umy, twz, fxu, dhd, pls, twt, dpz,